Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy

MADRIGAL PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$3.32 revenue$137,250,000

Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.
Operating expenses $216.6M (up 42% YoY) driven by SG&A for Rezdiffra launch; R&D fell to $44.2M.
Cash, equivalents, restricted cash and marketable securities $848.1M at March 31, 2025.
Appointed David Soergel, M.D. as CMO; Jacqualyn Fouse, Ph.D. to Board of Directors.
Two-year F4c cirrhosis data from MAESTRO-NAFLD-1 accepted as EASL late-breaker (May 7–10).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.